Table 2 Comorbidities and treatments before and after the stabilised IPTW using propensity scores
Variables | All patients | Patients after IPTW estimation | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
mPSL alone group (n = 2602) | % | rTM group (n = 212) | % | SMD | mPSL alone group (n = 2611) | % | rTM group (n = 190) | % | SMD | |
Comorbidity | ||||||||||
Bronchial asthma | 141 | 5.4 | 13 | 6.1 | 3.1 | 141 | 5.4 | 7 | 3.7 | − 8.2 |
Pulmonary emphysema | 101 | 3.9 | 7 | 3.3 | − 3.1 | 99 | 3.8 | 5 | 2.6 | − 7.1 |
Pneumonia | 488 | 18.8 | 48 | 22.6 | 9.6 | 500 | 19.1 | 36 | 18.9 | − 0.4 |
Mycotic infection | 16 | 0.6 | 6 | 2.8 | 17.1 | 22 | 0.8 | 2 | 1.1 | 0.2 |
Pulmonary embolism | 14 | 0.5 | 0 | 0 | − 10.4 | 15 | 0.6 | 0 | 0.0 | − 10.8 |
Bronchiectasis | 79 | 3.0 | 6 | 2.8 | − 1.2 | 78 | 3.0 | 4 | 2.1 | − 3.8 |
Pneumothorax | 23 | 0.9 | 2 | 0.9 | 0.6 | 23 | 0.9 | 1 | 0.5 | − 2.0 |
Cor pulmonale | 27 | 1.0 | 5 | 2.4 | 10.2 | 29 | 1.1 | 2 | 1.1 | 0.9 |
Lung cancer | 214 | 8.2 | 20 | 9.4 | 4.3 | 218 | 8.3 | 13 | 6.8 | − 6.2 |
Other types of cancera | 187 | 7.2 | 12 | 5.7 | − 6.2 | 184 | 7.0 | 10 | 5.3 | − 6.7 |
Sepsis | 59 | 2.3 | 10 | 4.7 | 13.4 | 67 | 2.6 | 12 | 6.3 | 19.3 |
Chronic heart failure | 362 | 13.9 | 23 | 10.8 | − 9.3 | 358 | 13.7 | 22 | 11.6 | − 6.4 |
Tachycardia | 186 | 7.1 | 12 | 5.7 | − 6.1 | 183 | 7.0 | 11 | 5.8 | − 5.9 |
Acute coronary syndrome | 171 | 6.6 | 11 | 5.2 | − 5.9 | 167 | 6.4 | 4 | 2.1 | − 17.6 |
Diabetes mellitus | 681 | 26.2 | 51 | 24.1 | − 4.9 | 676 | 25.9 | 43 | 22.6 | − 6.9 |
Stroke | 146 | 5.6 | 9 | 4.2 | − 6.3 | 143 | 5.5 | 9 | 4.7 | − 2.7 |
Dementia | 66 | 2.5 | 2 | 0.9 | − 12.2 | 63 | 2.4 | 2 | 1.1 | − 12.0 |
Renal failure | 272 | 10.5 | 27 | 12.7 | 7.1 | 281 | 10.8 | 18 | 9.5 | − 4.7 |
Liver dysfunction | 123 | 4.7 | 10 | 4.7 | 0 | 123 | 4.7 | 15 | 7.9 | 15.9 |
Gastroesophageal reflux disease | 339 | 13.0 | 23 | 10.8 | − 6.7 | 335 | 12.8 | 24 | 12.6 | − 0.8 |
Treatment within 3 days after hospitalisation | ||||||||||
Noradrenaline | 21 | 0.8 | 4 | 1.9 | 9.4 | 24 | 0.9 | 2 | 1.1 | 3.1 |
Azithromycin | 520 | 20.0 | 71 | 33.5 | 30.8 | 547 | 20.9 | 34 | 17.9 | − 6.9 |
Cyclophosphamide (intravenous) | 61 | 2.3 | 14 | 6.6 | 20.7 | 72 | 2.8 | 7 | 3.7 | 4.5 |
Cyclosporin | 88 | 3.4 | 15 | 7.1 | 16.6 | 98 | 3.8 | 11 | 5.8 | 9.2 |
Tacrolimus | 27 | 1.0 | 18 | 8.5 | 35.5 | 42 | 1.6 | 3 | 1.6 | 0.2 |
Azathioprine | 9 | 0.3 | 0 | 0 | − 8.3 | 9 | 0.3 | 0 | 0.0 | − 8.2 |
Pirfenidone | 49 | 1.9 | 18 | 8.5 | 30.1 | 62 | 2.4 | 4 | 2.1 | − 0.4 |
Nintedanib | 32 | 1.2 | 7 | 3.3 | 13.9 | 35 | 1.3 | 4 | 2.1 | 4.4 |
Sivelestat sodium hydrate | 341 | 13.1 | 72 | 34.0 | 50.6 | 385 | 14.7 | 32 | 16.8 | 5.7 |
Heparin calcium (intravenous) | 52 | 2.0 | 0 | 0 | − 20.2 | 51 | 2.0 | 0 | 0.0 | − 19.9 |
Dalteparin | 20 | 0.8 | 1 | 0.5 | − 3.8 | 19 | 0.7 | 0 | 0.0 | − 7.7 |
Tranexamic acid | 95 | 3.7 | 2 | 0.9 | − 18.1 | 90 | 3.4 | 4 | 2.1 | − 8.3 |
Haemodialysis | 96 | 3.7 | 14 | 6.6 | 13.2 | 104 | 4.0 | 11 | 5.8 | 7.6 |
High-flow nasal cannula oxygen therapy | 164 | 6.3 | 22 | 10.4 | 14.8 | 172 | 6.6 | 13 | 6.8 | 0.7 |
Fresh frozen plasma transfusion | 25 | 1.0 | 8 | 3.8 | 18.5 | 32 | 1.2 | 7 | 3.7 | 16.4 |
Concentrated platelet transfusion | 21 | 0.8 | 9 | 4.2 | 22.0 | 28 | 1.1 | 3 | 1.6 | 3.2 |